Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palmitate 3 month formulation (PP3M) in participants with schizophrenia previously adequately treated with paliperidone palmitate 1 month formulation (PP1M) for at least 4 months.
Critère d'inclusion
- Schizophrenia